옵션 체인은 다양한 행사가격과 만기일에 대한 Vivos Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Vivos Therapeutics에 대한 시장 심리를 평가합니다..

Vivos Therapeutics (NASDAQ:VVOS) 주식, 옵션 체인

Vivos Therapeutics

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Equities

News

Markets

NVDA

SOFI

TMUS

TSLA

VVOS

수요일 주식 시장은 연방준비제도(연준)의 0.5% 금리 인하 발표로 인해 하락세로 돌아섰다. 이는 2020년 3월 이후 처음으로 미 중앙은행의 매우 기대받던 금리 인하 사이클의 시작을 알리는 것이다.

수요일 주목받은 주식 5종목: 엔비디아, T-모바일, 비보스 테라퓨틱스, 소파이 및 테슬라

Vivos Therapeutics Inc

Loop Capital analyst Alan Gould maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and raises the price target from $180 to $210.

Price Target

Analyst Ratings

RDDT

Loop Capital Maintains Buy on Reddit, Raises Price Target to $210

Jefferies analyst Randal Konik maintains SharkNinja (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) with a Buy and raises the price target from $150 to $175.

Jefferies Maintains Buy on SharkNinja, Raises Price Target to $175

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $28 to $17.

STAA

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $17

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Buy and lowers the price target from $20 to $18.

Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $18

This dividend is payable on March 5, 2025 to shareholders of record on February 24, 2025. This dividend rate equates to an annualized dividend of $1.87 per share.

Dividends

CHCT

Community Healthcare Trust Boosts Quarterly Dividend From $0.4650 To $0.4675 Per Share

Offerings

Gen Digital Prices $950M Of Its 6.25% Senior Notes Due 2033, Which Were Offered In Private Offering

The sanction hearing for the Royal Court of Jersey (the "Court") to hear Arcadium Lithium's application to sanction the scheme of arrangement under Part 18A of the Companies (Jersey) Law 1991 has been set on March 5, 2025 at 5:00 a.m. EST (9:00 p.m. AEDT), with closing of the Transaction expected to occur shortly thereafter on March 6, 2025.
 &nbsp;

ALTM

Arcadium Lithium Gets All Required Pre-closing Regulatory Approvals In Connection With Proposed Acquisition Of By Rio Tinto

JFrog, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) reported its fourth-quarter results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/b43712041/jfrog-announces-fourth-quarter-and-fiscal-2024-results">details from the report. </a>
The Details:&nbsp;JFrog reported quarterly earnings of&nbsp;19&nbsp;cents per share which beat the analyst consensus estimate of&nbsp;14&nbsp;cents. Quarterly revenue clocked in at $116.08 million&nbsp;which beat the analyst consensus estimate of&nbsp;$114.19 million&nbsp;and is an increase over revenue of&nbsp;$97.26 million from&nbsp;the same period last year.
Read Next: <a href="https://www.benzinga.com/25/02/43667841/inflation-is-hot-and-getting-hotter">Inflation Runs Hot In January: &#8216;Houston We Have A Problem,&#8217; Experts Warn</a>&nbsp;
&#8220;The landscapes of DevOps, DevSecOps, and MLOps are evolving rapidly, with customer demand for comprehensive, end-to-end solutions that unify and secure the software supply chain, while enabling responsible GenAI adoption. These transformative shifts contributed to our success throughout 2024,&#8221; said Shlomi Ben Haim, CEO of JFrog. 
&#8220;In 2024, JFrog achieved strong cloud expansion, accelerated Platform adoption, and growth in security, all while delivering high Operating Cash Flow and Free Cash Flow performance. We have solidified our position as the single system of record for all types of software packages and AI models, and we remain committed to amplifying this momentum in 2025,&#8221; Haim added. 
Outlook: JFrog expects first-quarter revenue in a range of $116 million to $118 million, versus the $117.37 million estimate, and EPS of between 15 cents and 17 cents, versus the 15-cent estimate.
The company sees fiscal 2025 revenue in a range of $499 million to $503 million, versus the $499.62 million estimate and EPS of between 67&nbsp;cents and 69 cents, versus the 66 cent estimate. 
FROG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, JFrog shares are up 6.3% after hours at $40.10 Thursday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a></li>
</ul>
Image: Shutterstock

Earnings

Movers

Tech

FROG

JFrog Shares Jump After Better-Than-Expected Q4 Results, Strong Forward Guidance

PDF Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDFS#NASDAQ">PDFS</a>) sees FY2025 sales of $206.385 million vs $213.23 million analyst estimate.

Guidance

PDFS

PDF Solutions Sees FY2025 Sales $206.385M vs $213.23M Est

Wynn Resorts Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) reported fourth-quarter financial results Thursday after the bell. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/b43711732/wynn-resorts-limited-reports-fourth-quarter-and-year-end-2024-results">of the report</a>.
<ul>
<li>Q4 Revenue: $1.84 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.77 billion</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: $2.42, versus estimates of $1.22</li>
</ul>
Operating revenue was flat on a year-over-year basis as revenue increased at Wynn Palace and at Las Vegas properties, but decreased at Wynn Macau and Encore Boston Harbor. Wynn invested $99 million in the fourth quarter into a joint venture building Wynn Al Marjan Island in the United Arab Emirates (UAE), which is expected to open in 2027. 
&#8220;We delivered strong quarterly performance in Las Vegas on very tough comparables and drove healthy market share in Macau led by strength in both premium mass and VIP,&#8221; said Craig Billings, CEO of Wynn Resorts.
&#8220;In addition, construction of the Wynn Al Marjan Island project in the UAE continued to advance, and the thirty-fifth floor of the hotel tower was recently completed. We are confident the resort will be a &#8216;must see&#8217; tourism destination in the UAE and will support strong long-term free cash flow growth.&#8221;
Related Link: <a href="https://www.benzinga.com/general/travel/25/02/43714300/airbnb-shares-climb-after-q4-revenue-beats-estimates">Airbnb Shares Climb After Q4 Revenue Beats Estimates</a>
Wynn said it repurchased approximately 2.14 million shares of its common stock during the quarter for $200.3 million. As of Dec. 31, the company had $813 million remaining under its share repurchase program. Wynn Resorts ended the fourth quarter with $2.43 billion in cash, and $10.54 billion in debt. 
Wynn&#8217;s board declared a cash dividend of 25 cents per share, payable on March 5 to shareholders of record as of Feb. 24. The company&#8217;s management team is currently discussing the quarter on a conference call that kicked off at 4:30 p.m. ET.
WYNN Price Action: <a href="http://benzinga.com/quote/wynn">Wynn Resorts shares</a> were volatile following the earnings release. After initially surging above $84 per share, the stock was approximately flat around $80.50 in after-hours trading at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Global

After-Hours Center

WYNN

Wynn Resorts Q4 Earnings: Strong Results At Wynn Palace, Las Vegas Properties Offset By Declines In Macau, Boston Harbor, Shares Muted

The Company's dividend is payable to stockholders of record on March 7, 2025, and is expected to be paid on March 25, 2025.

Knight-Swift Transportation Increases Quarterly Cash Dividend From $0.16 To $0.18 Per Share

Payfare Says ISS Reiterated Recommendation That Shareholders Vote For Arrangement With Fiserv

S&amp;P 500 constituent Stryker Corp. is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions.&nbsp;

NARI

Kadant To Replace Inari Medical In S&P SmallCap 600 Effective Prior To The Opening Of Trading On February 19

PDF Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDFS#NASDAQ">PDFS</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.21 by 19.05 percent. This is a 66.67 percent increase over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $50.09 million which beat the analyst consensus estimate of $49.26 million by 1.67 percent. This is a 21.79 percent increase over sales of $41.13 million the same period last year.

Earnings Beats

PDF Solutions Q4 Adj $0.25 Beats $0.21 Estimate, Sales $50.09M Beat $49.26M Estimate

While the 2025 and 2026 gold production guidance is slightly lower than the prior three-year guidance issued on February 15, 2024 (primarily as a result of the deferral of processing low margin ore), the outlook for 2027 has improved as expected contributions in 2027 from East Gouldie at Canadian Malartic, LaRonde and Macassa are expected to offset lower gold grade sequences at Detour Lake and a decline in production at Meadowbank.

Agnico Eagle Mines Expects Gold Production Forecast To Remain Stable At 3.30 - 3.50 Million Ounces Annually In 2025 To 2027, Consistent With 2024, And 3% Lower Than Prior Guidance In Years 2025 And 2026

MTNB

Matinas BioPharma Enters Deal For Acquisition Of Certain Preferred Stock, Appoints Robin L. Smith To Board

Tucows (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCX#NASDAQ">TCX</a>) reported quarterly losses of $(1.43) per share. This is a 33.18 percent increase over losses of $(2.14) per share from the same period last year. The company reported $93.10 million in sales this quarter. This is a 7.06 percent increase over sales of $86.96 million the same period last year.

Tucows Q4 Adj $(1.43) Up From $(2.14) YoY, Sales $93.10M Up From $86.96M YoY

Buybacks

Tucows Plans To Repurchase Up To $40M Of Its Common Stock In The Open Market

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.18 by 6.78 percent. The company reported quarterly sales of $2.22 billion which missed the analyst consensus estimate of $2.27 billion by 2.01 percent.&nbsp;

Earnings Misses

Agnico Eagle Mines Q4 2024 Adj EPS $1.26 Beats $1.18 Estimate, Sales $2.22B Miss $2.27B Estimate

Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) reported its first-quarter results after Thursday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/02/g43711703/applied-materials-announces-first-quarter-2025-results">figures from the quarter</a>.
The Details:&nbsp;Applied Materials reported quarterly earnings of $2.38 per share which beat the $2.29 analyst consensus estimate. Quarterly revenue came in at $7.17 billion, beating the&nbsp;$7.14 billion consensus estimate. 
Read Next: <a href="https://www.benzinga.com/25/02/43667841/inflation-is-hot-and-getting-hotter">Inflation Runs Hot In January: &#8216;Houston We Have A Problem,&#8217; Experts Warn</a>&nbsp;
&#8220;The industry drive to accelerate the development of advanced compute and more sophisticated AI is gaining momentum,&#8221; said Gary Dickerson, CEO of Applied Materials. 
&#8220;Applied Materials is enabling the major device architecture inflections critical for energy-efficient AI and our focus on high-velocity co-innovation creates unique collaboration opportunities with our customers and partners, positioning Applied for continued growth and outperformance in the years to come,&#8221; Dickerson added. 
Outlook:&nbsp;The company sees second-quarter earnings of $2.30 per share, plus or minus 18 cents, versus the $2.30 estimate and revenue of $7.1 billion, plus or minus $400 million, versus the $7.21 billion estimate. 
AMAT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Applied Materials shares are down 5.41% after hours at $174.30 Thursday.&nbsp;&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a></li>
</ul>
Image: Shutterstock

AMAT

Applied Materials Stock Slides After Q1 Report, Weak Q2 Revenue Guidance

Vivos surges on FDA nod for pediatric sleep apnea device

Vivos Therapeutics announces $4.3M registered direct offering of common stock

Vivos Therapeutics, Inc. ( ($VVOS) ) has released its Q3 earnings. Here is a breakdown of the information Vivos Therapeutics, Inc. presented to its...

Vivos Therapeutics Reports Revenue Growth and Strategic Milestones

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Vivos Therapeutics GAAP EPS of -$0.40, revenue of $3.86M

Vivos Therapeutics (VVOS) has entered into definitive agreements for the purchase and sale of an aggregate of 709,220 shares of its common stock at...

Vivos to sell 709,220 shares at $4.935 in registered direct offering

Check out this morning's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER – Despegar.com&nbsp;(DESP) up 33% after Prosus annou...

Morning Movers: Despegar surges following deal to be acquired by Prosus

Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders

Vivos Therapeutics announces up to $50M mixed shelf offering

16:27 EST Vivos Therapeutics (VVOS) files $50M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving ...

Vivos Therapeutics files $50M mixed securities shelf

APLT

DESP

HNDAF

PLYA

Penny Stocks

Health Care

Press Releases

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

General

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

FDA Approval Sends Shares of this Healthcare Company Higher

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Nutex Health

Ontrak

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

Comments

Vivos Therapeutics

Vivos Therapeutics (VVOS) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌